Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Free Report) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 5,280,000 shares, a drop of 5.9% from the March 15th total of 5,610,000 shares. Based on an average trading volume of 1,200,000 shares, the short-interest ratio is presently 4.4 days.
Alpine Immune Sciences Trading Down 0.0 %
Shares of ALPN stock traded down $0.01 on Tuesday, reaching $64.41. The company’s stock had a trading volume of 1,703,091 shares, compared to its average volume of 1,860,567. The stock’s fifty day simple moving average is $37.16 and its 200-day simple moving average is $23.49. Alpine Immune Sciences has a 1 year low of $6.71 and a 1 year high of $64.57. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of -100.66 and a beta of 1.14.
Alpine Immune Sciences (NASDAQ:ALPN – Get Free Report) last posted its earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The firm had revenue of $30.85 million during the quarter, compared to analyst estimates of $6.90 million. Equities research analysts forecast that Alpine Immune Sciences will post -1.74 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of research firms have commented on ALPN. Leerink Partnrs cut shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 11th. Morgan Stanley restated an “equal weight” rating and set a $65.00 target price (up previously from $47.00) on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. Wolfe Research reiterated a “peer perform” rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Oppenheimer reiterated an “outperform” rating and set a $44.00 price objective (up previously from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Finally, Wedbush cut shares of Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a research report on Thursday, April 11th. Eight investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $50.33.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.
Read More
- Five stocks we like better than Alpine Immune Sciences
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Silicon Motion Proves That AI in Motion Stays in Motion
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Undervalued UnitedHealth Group Won’t Be For Long
- How to Invest in Blue Chip Stocks
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.